| __timestamp | Alnylam Pharmaceuticals, Inc. | Regeneron Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 1271353000 |
| Thursday, January 1, 2015 | 276495000 | 1620577000 |
| Friday, January 1, 2016 | 382392000 | 2052295000 |
| Sunday, January 1, 2017 | 390635000 | 2075142000 |
| Monday, January 1, 2018 | 505420000 | 2186100000 |
| Tuesday, January 1, 2019 | 655114000 | 3036600000 |
| Wednesday, January 1, 2020 | 654819000 | 2735000000 |
| Friday, January 1, 2021 | 792156000 | 2908100000 |
| Saturday, January 1, 2022 | 883015000 | 3592500000 |
| Sunday, January 1, 2023 | 1004415000 | 4439000000 |
| Monday, January 1, 2024 | 1126232000 | 5132000000 |
Unlocking the unknown
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.
Regeneron has consistently outpaced Alnylam in R&D expenditure, with a remarkable 250% increase from 2014 to 2023. By 2023, their R&D spending reached nearly $4.44 billion, underscoring their leadership in the biotech sector.
Alnylam, while smaller in scale, has shown impressive growth, with R&D expenses rising by over 400% during the same period. Their 2023 expenditure of approximately $1 billion highlights their strategic focus on pioneering RNA interference therapeutics.
This data not only showcases the financial commitment of these companies but also their pivotal role in driving innovation in the pharmaceutical industry.
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Viatris Inc.
Regeneron Pharmaceuticals, Inc. or Jazz Pharmaceuticals plc: Who Invests More in Innovation?
R&D Insights: How Regeneron Pharmaceuticals, Inc. and PTC Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Alpine Immune Sciences, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Ionis Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Corcept Therapeutics Incorporated
R&D Insights: How Alnylam Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. Allocate Funds
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Viking Therapeutics, Inc.
Research and Development Expenses Breakdown: Alnylam Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
Alnylam Pharmaceuticals, Inc. vs Iovance Biotherapeutics, Inc.: Strategic Focus on R&D Spending
Comparing Innovation Spending: Alnylam Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.